For Identifying Destructive Heart Changes, Harvard Researcher Wins Prize
Main Category: Cardiovascular / CardiologyAlso Included In: Clinical Trials / Drug Trials
Article Date: 05 Nov 2007 - 3:00 PDT
| Patient / Public: | ![]() |
1 (1 votes) |
| Healthcare Prof: | ![]() |
4 (2 votes) |
The American Heart Association awarded its Clinical Research Prize to a Harvard researcher for identifying destructive structural changes in the diseased heart and leading clinical trials showing that lifesaving therapies can limit damage.
Marc Alan Pfeffer, M.D., Ph.D., Dzau Professor of Medicine at Harvard and Brigham and Women's Hospital in Boston, received the award during the American Heart Association's Scientific Sessions 2007 at the Orange County Convention Center.
"Dr. Pfeffer's trailblazing investigations exponentially expanded our knowledge of the damage that hypertension and heart attacks inflict on cardiac muscle tissue, and what can be done to overcome this damage," said Daniel Jones, M.D., American Heart Association president, who presented the $5,000 prize recognizing major achievement in clinical cardiovascular science.
Dr. Pfeffer's demonstration of adverse structural changes in the heart -- a process called ventricular remodeling -- "opened the way to highly effective treatment approaches designed to reverse this destructive process," Jones said.
After showing that ventricular remodeling leads to potentially fatal heart failure, Pfeffer led the first major clinical trial establishing that angiotensin-converting enzyme (ACE) inhibitors can slow or reverse these adverse structural changes. The Survival and Ventricular Enlargement (SAVE) trial demonstrated the efficacy of ACE inhibitors to treat acute heart attack and chronic heart failure.
"This historic trial paved the way for numerous other investigations expanding and elaborating on the effective use of these medications to improve survival and reduce morbidity," Jones said.
Pfeffer, who leads a large clinical research department, is principal investigator of international trials testing novel approaches to reduce cardiovascular risk.
###
Source: Karen Astle
American Heart Association
Visit our cardiovascular / cardiology section for the latest news on this subject.
MLA
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/87667.php>
APA
http://www.medicalnewstoday.com/releases/87667.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.





